Mobocertinib and Bevacizumab for Amivantamab-Refractory Lung Cancer With EGFR Exon 20 Insertion Mutation: A Case Report

被引：0
|
作者：
Kim, Jaemin [1 ]
Lee, Youngjoo [1 ,2 ,3 ]
机构：
[1] Natl Canc Ctr, Res Inst, Goyang, South Korea
[2] Natl Canc Ctr, Dept Internal Med, Div Hematol & Oncol, Goyang, South Korea
[3] Natl Canc Ctr, Dept Internal Med, Div Hematol & Oncol, 323 Ilsan Ro, Goyang 10408, South Korea
来源：
JTO CLINICAL AND RESEARCH REPORTS | 2023年 / 4卷 / 12期
关键词：
NSCLC; EGFR exon 20 insertion; Drug resistance; Anti-angiogenesis; Targeted therapy; Case report; GROWTH;
D O I：
10.1016/j.jtocrr.2023.100600
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Amivantamab is the first drug approved in EGFR exon 20 insertion-mutated NSCLC. Nevertheless, primary or secondary resistance to amivantamab is a frequent problem in clinical practice. We report a case of a patient with EGFR exon 20-mutated NSCLC who had primary resistance to amivantamab but was successfully treated by combining therapy of another EGFR exon 20 insertion-specific targeted drug mobocertinib and bevacizumab.(c) 2023 The Authors. Published by Elsevier Inc. on behalf of the International Association for the Study of Lung Cancer. This is an open access article under the CC BY-NC-ND li-cense (http://creativecommons.org/licenses/by-nc-nd/ 4.0/).
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Targeting EGFR Exon 20 Insertion Mutation in Non-small cell Lung Cancer: Amivantamab and Mobocertinib
    Russell, Molly C.
    Garelli, Alyssa M.
    Reeves, David J.
    [J]. ANNALS OF PHARMACOTHERAPY, 2023, 57 (02) : 198 - 206
  • [2] Amivantamab and Mobocertinib in Exon 20 insertions EGFR Mutant Lung Cancer, Challenge To The Current Guidelines
    Olivier, Timothee
    Prasad, Vinay
    [J]. TRANSLATIONAL ONCOLOGY, 2022, 23
  • [3] Severe Psychiatric Symptoms in a Patient With EGFR Exon-20 Insertion Mutation Receiving Mobocertinib: A Case Report
    Kamel, Josette
    Meeder, Natalie
    Cuellar, Sandra
    Chan, David
    Huber, Michael
    Pasquinelli, Mary
    Hulbert, Alicia
    Khaddour, Karam
    Feldman, Lawrence
    [J]. JTO CLINICAL AND RESEARCH REPORTS, 2021, 2 (11):
  • [4] EGFR exon 20 insertion mutation in Japanese lung cancer
    Sasaki, Hidefumi
    Endo, Katsuhiko
    Takada, Minoru
    Kawahara, Masaaki
    Kitahara, Naoto
    Tanaka, Hisaichi
    Okumura, Meinoshin
    Matsumura, Akihide
    Luchi, Keiji
    Kawaguchi, Tomoya
    Kawano, Osamu
    Yukiue, Haruhiro
    Yokoyama, Tomoki
    Yano, Motoki
    Fujii, Yoshitaka
    [J]. LUNG CANCER, 2007, 58 (03) : 324 - 328
  • [5] Response to Mobocertinib in a patient with advanced Non-Small Cell Lung Cancer harboring EGFR exon 20 insertion after several therapies including Amivantamab
    de la Fuente, Elena Corral
    Garcia, Maria Eugenia Olmedo
    Martin, Inmaculada Orejana
    Berlinches, Amparo Benito
    Rueda, Ana Gomez
    Alfranca, Yolanda Lage
    Garrido, Pilar
    [J]. CURRENT PROBLEMS IN CANCER: CASE REPORTS, 2022, 5
  • [6] Amivantamab for the treatment of EGFR exon 20 insertion mutant non-small cell lung cancer
    Vyse, Simon
    Huang, Paul H.
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2022, 22 (01) : 3 - 16
  • [7] MATCHING-ADJUSTED INDIRECT COMPARISON OF AMIVANTAMAB VS. MOBOCERTINIB IN EGFR EXON 20 INSERTION-MUTATED NON-SMALL CELL LUNG CANCER
    Van Sanden, S.
    Rahhali, N.
    Schioppa, C.
    Diels, J.
    Rodrigues, B.
    Chandler, C.
    Kapetanakis, V
    Jain, R.
    Li, T.
    [J]. VALUE IN HEALTH, 2022, 25 (07) : S526 - S526
  • [8] Real-world efficacy and safety of mobocertinib in EGFR exon 20 insertion-mutated lung cancer
    Kian, Waleed
    Christopoulos, Petros
    Remilah, Areen A.
    Levison, Esther
    Dudnik, Elizabeth
    Shalata, Walid
    Krayim, Bilal
    Marei, Ranin
    Yakobson, Alexander
    Faehling, Martin
    Kahala, Dolev
    Sara Granot, Inbal
    Levitas, Dina
    Peled, Nir
    Roisman, Laila C.
    [J]. FRONTIERS IN ONCOLOGY, 2022, 12
  • [9] Secondary Mutations of the EGFR Gene That Confer Resistance to Mobocertinib in EGFR Exon 20 Insertion
    Hamada, Akira
    Suda, Kenichi
    Nishino, Masaya
    Obata, Keiko
    Oiki, Hana
    Fukami, Tomoyo
    Fukuda, Shota
    Fujino, Toshio
    Ohara, Shuta
    Koga, Takamasa
    Chiba, Masato
    Shimoji, Masaki
    Ito, Masaoki
    Takemoto, Toshiki
    Soh, Junichi
    Tsutani, Yasuhiro
    Mitsudomi, Tetsuya
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (01) : 71 - 79
  • [10] Amivantamab in Post-platinum EGFR Exon 20 Insertion Mutant Non-small Cell Lung Cancer
    Sabari, J. K.
    Shu, C. A.
    Park, K.
    Leighl, N.
    Mitchell, P.
    Kim, S.
    Lee, J.
    Kim, D.
    Viteri, S.
    Spira, A.
    Han, J.
    Trigo, J.
    Lee, C. K.
    Lee, K. H.
    Girard, N.
    Yang, T.
    Goto, K.
    Sanborn, R. E.
    Yang, J. C.
    Xie, J.
    Roshak, A.
    Thayu, M.
    Knoblauch, R. E.
    Cho, B. C.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S108 - S109
12345